Navigation Links
New Topical Painkiller Relieves Severe Pain in Minutes
Date:4/13/2009

ENCINO, Calif., April 13 /PRNewswire/ bluMjk (pronounced "Blue Magic"), a new over-the-counter topical painkiller, uses patent pending skin and nerve penetrating technology to relieve the majority of moderate to severe pain experienced by most pain sufferers. Within minutes of a topical application, bluMjk restores pain nerve fibers to their natural resting state, which eliminates the sensation of pain. R & S Research developed this new penetrating technology to quickly and safely deliver the active ingredient, salicylate, deep into the skin and target nerve cells without any side- effects.

Salicylate has historically been an effective oral pain reliever acting as a Non-Steroidal Anti-Inflammatory Drug, with the same mode of action as aspirin or ibuprofen. Topically, applied bluMjk works much faster and much more powerfully to relieve moderate to severe pain in a wide variety of pain conditions.

The unique combination of all natural ingredients which comprise the carrier system of this new formulation bring the active ingredient, salicylate, through the layers of the skin and then through the cell membrane of the nerves that transmit the sensation of pain to the brain. Because of the speed with which bluMjk works the R & S Research team concluded the effect of bluMjk on these pain nerves is to shut off their output and restore them to a resting state. Because bluMjk is not an anesthetic it has no effect on any other nerves, and sensations of touch, pressure, hot, cold, etc are unaffected by this medication. Since the effect of bluMjk takes place where the pain originates there is no effect on the brain and therefore no chance of habituation or addiction. bluMjk is as powerful as a narcotic and as safe as aspirin.

bluMjk has been used in a large variety of clinical pain syndromes effectively, including tension and migraine headaches, both osteo and rheumatoid arthritis, various nerve inflammations including herpes zoster (shingles), and has been found to be effective in almost every type of peripheral pain including muscle and joint pain of almost any origin. Interestingly, this medication has been effective in some extremely hard to treat conditions such as TemperoMandibular Joint disease and the chronic severe intractable nerve pain that may occur in some cases of shingles. One of the most resistant pain conditions afflicting the human race, Reflex Sympathetic Dystrophy or CRPS, has been shown to be responsive to bluMjk on an anecdotal basis.

Pain relief after using bluMjk typically lasts four to six hours. Clearly, the quality of life of many pain sufferers can now take a turn for the better.

http://www.blumjk.com

About:

R & S Research, LLC, located in Encino, CA, is a manufacturer and wholesaler of over the counter pharmaceuticals based on the company's proprietary skin and cell membrane penetrating technologies. It is dedicated to the mission of developing unique products that have no existing counterparts. It is doctor owned and operated. http://www.rs-research.com

     Contact:
     Galen Weaver, Media Relations
     R & S Research
     galen@rs-research.com
     360-356-0496

'/>"/>
SOURCE R & S Research
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Topical Dermatological Product Development in the USA Workshop to Be Held on June 4, 2009 in East Brunswick, New Jersey, USA
2. Chronic Pain Sufferers Report Relief: DRJ Group Teams With Adult Foster Care Facilities to Evaluate Effectiveness of Stopain Topical Analgesic
3. Topical Spray Helped Men With Premature Ejaculation
4. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
5. Global Warming Expected to Spike Pollen and Spring Allergies - New Drug-Free Topical Gels Boost Hope for Allergy Sufferers
6. Study Shows Nonprescription LCD Topical Solution is More Effective than Prescription-Strength Calcipotriol Cream for Moderate Plaque Psoriasis
7. The Texas Institute of Dermatology Team Finds Easy-to-Apply, Topical Drug Just as Good as Injectable Compound for a Disfigurating Skin Infection
8. NanoBio to Announce Key Clinical and Preclinical Data on Its Topical Anti-infective Lotions at AAD 2009
9. American Academy of Dermatology Issues New Guidelines For The Management of Psoriasis With Topical Therapies
10. High and Super-High Potency Topical Corticosteroids Will Remain Decision Resources Clinical Gold Standard Through 2017 for the Treatment of Atopic Dermatitis
11. Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/24/2017)... ... , ... Indosoft Inc. announces the availability of Q-Suite NG version 1.01. Q-Suite ... experience. It represents a complete redesign of their popular Q-Suite product to meet the ... integration. A full set of APIs allows it to be used as a platform ...
(Date:8/23/2017)... ... 23, 2017 , ... The Arc Mercer, Capitol County’s premier provider of programs ... LGBTQ community organization for people with special needs. The group, the Special Needs Alliance ... state of New Jersey – but the first in the entire country! , SNAP ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... Business Development and Sector Growth. Mr. Smith joins other recent high-profile hires including ... Mr. Smith’s healthcare career began in 1993, helping physician practices and hospitals automate ...
(Date:8/23/2017)... ... August 23, 2017 , ... Based on worldwide research ... efficacy of HBOT in treating and helping to heal addictions and substance abuse ... the similarities of the wounds to the brain from traumatic brain injuries, and ...
(Date:8/23/2017)... ... 23, 2017 , ... Nightingale College continues the semiannual Give Back Day tradition ... Nightingale College dedicates to serving and volunteering for organizations that provide indispensable resources to ... those that need a little extra help. , The College’s Give Back Day ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
(Date:8/7/2017)... WARSAW, Ind. , Aug. 7, 2017 Zimmer ... in musculoskeletal healthcare, today announced that its Board of Directors ... stockholders for the third quarter of 2017. ... will be paid on or about October 27, 2017 to ... September 22, 2017.  Future declarations of dividends are subject to ...
(Date:8/7/2017)... 2017  Endo International plc (NASDAQ: ENDP ... virtually all known U.S. mesh product liability claims and ... known remaining U.S. claims at reasonable values. Under the ... fourth quarter of 2017 and continuing through the fourth ... 2017 results, the Company intends to increase its mesh ...
Breaking Medicine Technology: